VIDEO: Primary generalized tonic-clonic seizures pressing health issue for adolescents

DENVER — Primary generalized tonic-clonic seizures present unique challenges to adolescents diagnosed with the condition, Sunita Misra, MD, PhD, said in this Healio video at the American Academy of Neurology annual meeting.

“We are looking to see if cenobamate is effective for primary generalized tonic-clonic seizures,” said Misra, vice president of global clinical development and acting chief medical officer for SK Life Science.

The company has commenced a clinical trial in adolescents aged 12 to 17 years with primary generalized tonic-clonic seizures and it is hoping to recruit patients in that age range for the study, as well as to raise awareness.

As seizures of this type are rare and can present with other forms of epilepsy syndromes, few current antiseizure medications have been effective in addressing the condition, she added.

In addition, these seizures carry high morbidity and high mortality rates, which are often accompanied by physical injury, cognitive impairment and psychiatric concerns.